COMPARISON OF TOTAL MEDICAL COST AVOIDANCE WITH THE USAGE OF NEW ORAL ANTICOAGULANTS INSTEAD OF WARFARIN AMONG ATRIAL FIBRILLATION PATIENTS, BASED ON THE ARISTOTLE, RE-LY AND ROCKET-AF TRIALS Article
Full Text via DOI: 10.1016/S0735-1097(12)60600-7
Web of Science: 000302326700601